Craft

Travere Therapeutics

Stock Price

$5.5

2024-04-29

Market Capitalization

$415.6 M

2024-04-29

Revenue

$145.2 M

FY, 2023

Travere Therapeutics Summary

Company Summary

Overview
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam, and Thiola. The Company also has a number of product candidates to treat various serious diseases.
Type
Public
Status
Active
Founded
2011
HQ
San Diego, CA, US | view all locations
Website
https://travere.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Gary A. Lyons, Chairman

    • Eric Dube

      Eric Dube, President & Chief Executive Officer

    • Peter Heerma

      Peter Heerma, Chief Commercial Officer

    • Tim Coughlin, Director

      LocationsView all

      2 locations detected

      • San Diego, CA HQ

        United States

        3721 Valley Centre Dr #200san

      • Dublin, D

        Ireland

        2nd Floor, Palmerston House, Fenian St

      Travere Therapeutics Financials

      Summary Financials

      Revenue (FY, 2023)
      $145.2M
      Gross profit (FY, 2023)
      $133.8M
      Net income (FY, 2023)
      ($111.4M)
      Cash (FY, 2023)
      $58.2M
      EBIT (FY, 2023)
      ($388.1M)
      Enterprise value
      $858.7M

      Blogs

      Footer menu